Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Brookdale Senior Living (BKD) and 10x Genomics (TXG)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Brookdale Senior Living (BKD) and 10x Genomics (TXG).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen (AMGN)
In a report released today, Emily Field from Barclays maintained a Hold rating on Amgen, with a price target of $350.00. The company’s shares closed last Monday at $350.16.
According to TipRanks.com, Field is a 3-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $368.86, implying a 4.1% upside from current levels. In a report issued on April 7, Citi also maintained a Hold rating on the stock with a $345.00 price target.
See today’s best-performing stocks on TipRanks >>
Brookdale Senior Living (BKD)
In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Brookdale Senior Living, with a price target of $18.00. The company’s shares closed last Monday at $13.54.
According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Brookdale Senior Living has an analyst consensus of Strong Buy, with a price target consensus of $19.10, representing a 39.6% upside. In a report issued on April 8, Stephens also initiated coverage with a Buy rating on the stock with a $18.00 price target.
10x Genomics (TXG)
Barclays analyst Luke Sergott maintained a Buy rating on 10x Genomics today and set a price target of $30.00. The company’s shares closed last Monday at $24.59.
According to TipRanks.com, Sergott is a 1-star analyst with an average return of
Currently, the analyst consensus on 10x Genomics is a Moderate Buy with an average price target of $22.83, which is a -11.7% downside from current levels. In a report issued on April 14, TipRanks – PerPlexity also upgraded the stock to Buy with a $26.00 price target.
Read More on AMGN:
